Zobrazeno 1 - 10
of 64
pro vyhledávání: '"S. M. O'Brien"'
Autor:
A. Mato, A. Danilov, M. R. Patel, M. Tees, I. Flinn, W. Ai, K. Patel, M. Wang, S. M. O’Brien, S. Nandakumar, M. Tan, E. Meredith, M. Gessner, S. Y. Kim, A. Wiestner, W. G. Wierda
Publikováno v:
HemaSphere, Vol 6, Pp 547-548 (2022)
Externí odkaz:
https://doaj.org/article/86f48eed24de4c4bb0433b3767c872f1
Publikováno v:
Conservation Science and Practice, Vol 3, Iss 11, Pp n/a-n/a (2021)
Abstract Private land comprises over half the land mass of the United States—dominating certain ecosystems and hosting large numbers of threatened and endangered species. Understanding privately owned properties is thus critically important to cons
Externí odkaz:
https://doaj.org/article/657ce2c1c7fb43bba707950470c612bc
Autor:
William A. Hopkins, Brian F. Case, Jordy Groffen, George C. Brooks, Catherine M. Bodinof Jachowski, Sky T. Button, John J. Hallagan, Rebecca S. M. O’Brien, Holly K. Kindsvater
Publikováno v:
The American Naturalist. :000-000
Publikováno v:
Conservation Science and Practice, Vol 3, Iss 11, Pp n/a-n/a (2021)
Private land comprises over half the land mass of the United States-dominating certain ecosystems and hosting large numbers of threatened and endangered species. Understanding privately owned properties is thus critically important to conservation, y
Autor:
Michaela Liedtke, S. M. O'Brien, Jane Liang White, Tao Wang, Matthias Stelljes, Barbara Sleight, M. Luisa Paccagnella, Wendy Stock, Anjali S. Advani, Elias Jabbour, Daniel J. DeAngelo, Nicola Gökbuget, Hagop M. Kantarjian, Erik Vandendries, Giovanni Martinelli
Publikováno v:
American Journal of Hematology. 94:408-416
Karyotype is frequently used to predict response and outcome in leukemia. This post hoc exploratory analysis evaluated the relationship between baseline cytogenetics and outcome in patients with relapsed/refractory acute lymphoblastic leukemia (R/R A
Autor:
William G. Wierda, S. M. O'Brien, John C. Byrd, Richard R. Furman, Jeff P. Sharman, Jennifer R. Brown, Paolo Ghia
Publikováno v:
Frontiers in Oncology
Frontiers in Oncology, Vol 11 (2021)
Frontiers in Oncology, Vol 11 (2021)
Bruton tyrosine kinase (BTK) inhibitors represent an important therapeutic advancement for B cell malignancies. Ibrutinib, the first-in-class BTK inhibitor, is approved by the US FDA to treat patients with chronic lymphocytic leukemia (CLL)/small lym
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5f574af02d334e40c95c855964f02d5f
Autor:
S. M. O'Brien, E. Vandendries, R.D. Cassaday, A. Neuhof, M. Stelljes, T. Wang, H. Kantarjian, W. Stock, A. Advani, D.I. Marks, E. Jabbour, D.J. DeAngelo
Publikováno v:
HemaSphere. 3:428-429
Autor:
D.I. Marks, E. Jabbour, D.J. DeAngelo, M. Stelljes, T. Wang, H. Kantarjian, A. Neuhof, Anjali S. Advani, S. M. O'Brien, R.D. Cassaday, W. Stock, E. Vandendries
Publikováno v:
HemaSphere. 3:427-428
Autor:
S M, O'Brien, A, Mouser, J E, Odon, C, Winter, T J, Draycott, T, Sumitro, D, Alisantoso, W L, Lim, M, Merialdi, A K, Stankovic, J F, Crofts
Publikováno v:
BJOG : an international journal of obstetrics and gynaecology. 124
To (1) determine how intended users interact with and use the BD Odon Device in simulation, (2) use these findings to alter progressively the design of the BD Odon Device and (3) validate that these changes have improved the ability of practitioners
Autor:
R.D. Cassaday, T. Wang, A. Neuhof, W. Stock, E. Vandendries, A. Advani, Nicola Gökbuget, D.I. Marks, S. M. O'Brien, D.J. DeAngelo, H. Kantarjian, E. Jabbour, M. Stelljes
Publikováno v:
HemaSphere. 3:428